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Nicotine replacement therapies (NRT) are an effective
treatment for tobacco dependence, yet most smokers do
not quit or remain abstinent. We investigated whether
Swedish snus (snuff) use was associated with smoking
cessation among males participating in a large population
based twin study in Sweden. Snus use was associated with
smoking cessation but not initiation. Given that snus delivers
comparable nicotine concentrations but carries lesser cancer
risk than cigarettes, snus may be a widely used, non-medical
form of NRT. Evaluation of the efficacy of snus for smoking
cessation should be evaluated in randomised clinical trials.
T
obacco use is the second major cause of death worldwide.
Nicotine replacement therapy (NRT) can double smoking
cessation rates, but most smokers receiving treatment do
not achieve long term abstinence.1 Additional NRT is needed.
The prevalence of cigarette smoking is notably low in
Sweden while the use of snus is increasing. Swedish snus is a
moist smokeless tobacco product that contains lower
concentrations of cancer-causing tobacco-specific nitros-
amines than found in other smokeless tobacco products
and cigarettes.2 While snus delivers similar concentrations of
nicotine, it carries substantially lower risks of cancer than
cigarettes.3–8 Male smokers in Sweden appear to be using
snus as a form of NRT,9 despite a lack of data from
randomised clinical trials to support its use as a smoking
cessation treatment.10
We investigated whether lifetime snus use was associated
with smoking initiation or cessation to gain insight into its
potential role as NRT. It is critical to examine snus’ potential
dual effects on smoking, given the fear that advocating the
use of snus might increase smoking, thereby mitigating its
utility as NRT.11–13
PARTICIPANTS, METHODS AND RESULTS
Data from the screening across lifespan twin study (SALT)
from the population based Swedish Twin Registry were
used.14 The study protocol was reviewed and approved by the
ethical committee of the Karolinska Institute, the Swedish
Data Inspection Board, and the Institutional Review Board at
the University of North Carolina at Chapel Hill.
All subjects provided written informed consent. Briefly,
SALT contains detailed data on tobacco use (type, amount,
age at first use, patterns of use, and Fagerstrom test for
nicotine dependence (FTND)) from telephone interviews
completed by 31 425 twins born in Sweden before 1959.
Participants who currently or formerly ‘‘smoke(d) at parties’’,
‘‘smoke(d) now and then’’, or ‘‘smoke(d) regularly’’ were
considered ‘‘ever smokers’’. Participants who ‘‘only tried
cigarettes’’ or ‘‘never smoked’’ were considered ‘‘never
smokers’’. We classified participants as ‘‘ever snus user’’ if
they currently or formerly used snus ‘‘now and then’’ or
‘‘regularly’’; otherwise they were classified as ‘‘never snus
user’’. The questionnaire did not specifically describe what
was meant by ‘‘regular’’ or ‘‘now and then’’ tobacco use,
rather it was up to the participant to interpret and select the
type of tobacco user they considered themselves to be. Since
the lifetime prevalence of any snus use was only 2.5% among
females, we restricted our analyses to males (n = 14 932).
To investigate whether snus use was associated with
smoking initiation, we compared men who used snus before
they started smoking to men who never used snus in relation
to any lifetime smoking (ever versus never ‘‘regular’’ or ‘‘now
and then’’ cigarette smokers). To address whether snus use
was associated with smoking cessation, we compared men
who used snus after they began smoking to men who never
used snus in relation to smoking status at the time of
interview (former versus current ‘‘regular’’ or ‘‘now and
then’’ smokers).
Odds ratios (OR) and 95% confidence intervals (CI) were
estimated with age adjusted logistic regression models and
generalised estimating equations to account for clustering of
twin pairs. Stratified analyses were performed to examine
whether the associations for smoking cessation remained in
subgroups of smokers (heavy versus light smokers; high
versus low FTND scores).
Table 1 presents the distributions of tobacco use. Of the
14 932 males that participated in SALT, 14 424 (96.6%) had
tobacco use data and ages at initiation. Of these men, 9151
(63.5%) reported smoking during their lifetime. Of the
smokers, 7880 (86.1%) reported that they smoke(d) ‘‘reg-
ularly’’, 669 (7.3%) smoke(d) ‘‘now and then’’, and 602
(6.6%) ‘‘smoke(d) at parties’’. The prevalence of current
smoking status was highest for ‘‘now and then’’ smokers
(39.2%) as compared with ‘‘regular’’ smokers (34.0%) and
‘‘party’’ smokers (23.1%). The prevalence of any lifetime snus
use in SALT was 28.5% (n = 4119), the majority of whom
used snus regularly (n = 3704, (89.9%)).
‘‘Regular’’ and ‘‘now and then’’ snus use were inversely
associated with smoking initiation (table 2). Only 4.1% of
men who ever smoked used snus ‘‘regularly’’ before they
started smoking, while 18.5% of non-smokers had used snus
‘‘regularly’’. The odds ratio (OR) for ‘‘regular’’ snus use and
ever smoking status was 0.2 (95% confidence interval (CI) 0.2
to 0.3). Despite smaller sample sizes, a similar pattern was
observed for men who reported they used snus ‘‘now and
then’’. Only 0.5% of men who ever smoked used snus ‘‘now
and then’’ before they started smoking, while 1.1% of never
smokers reported that they used snus ‘‘now and then’’. ‘‘Now
and then’’ snus use was also inversely associated with ever
smoking status (OR 0.5, 95% CI 0.3 to 0.7), suggesting that
men who used snus ‘‘regularly’’ or ‘‘now and then’’ before
they began smoking were less likely to ever smoke.
Abbreviations: FTND, Fagerstrom test for nicotine dependence; NRT,
nicotine replacement therapy; SALT, screening across lifespan twin study
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‘‘Regular’’ snus use was associated with smoking cessation
among ‘‘regular’’ and ‘‘now and then’’ smokers (table 3). The
proportion of former smokers who used snus ‘‘regularly’’
(34.6%) was higher than the proportion of current smokers
who used snus regularly (13.7%). The OR for ‘‘regular’’ snus
use and former smoking status was 3.7 (95% CI 3.3 to 4.2),
indicating that men who used snus ‘‘regularly’’ were over
three times more likely to be former smokers than current
smokers. No association was observed between ‘‘now and
then’’ snus use and smoking cessation (OR 1.1, 95% CI 0.9 to
1.4). Thus, it appears that only ‘‘regular’’ snus use has an
impact on smoking cessation.
DISCUSSION
Consistent with recent studies,2 9 15–19 we observed that snus
use was associated with smoking cessation, not initiation.
Our results support the idea that snus is a type of naturalistic
and non-medical NRT that smokers in Sweden may be using
to enhance smoking cessation efforts.9 We acknowledge the
cross sectional nature of our data and assert that this
correlation is not necessarily causal. Taken together with the
information presented in a recent debate over the potential of
snus as a smoking cessation aide,2 we suggest that
randomised clinical trials are needed to investigate the utility
and risks of snus as NRT under controlled conditions.
We are aware that advocating the use of one addictive
tobacco product to diminish the harm from another is a
controversial issue, particularly as data supporting the use of
snus as NRT could enhance the market of the tobacco
industry. Clearly, eliminating all forms of tobacco use would
have the most beneficial impacts on world health; however,
many smokers are unable to achieve lasting smoking
cessation. From a harm reduction perspective, should snus
be shown to be as effective as or superior in efficacy to
existing NRTs without having adverse health consequences,
it may represent a more acceptable means by which to reduce
tobacco related health burden.
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Table 1 Distributions of cigarette smoking and snus use among males in the Swedish Twin Registry
Ever smoker (n = 9151, 63.5%) Never smoker
(n = 5273, 36.5%)
Ever regular smoker
(n =7880, 86.1%)
Ever now and then smoker
(n = 669, 7.3%)
Ever party smoker*









(n = 262, 39.2%)
Former now and
then smoker
(n = 407, 60.8%)
Current party
smoker




Regular snus use (n = 3704, 25.6%)
Began using snus before cigarettes 61 147 16 38 . . NA
Began using snus after cigarettes 324 1701 57 70 . . NA
Only used snus, no cigarettes NA NA NA NA NA NA 976
Began using both at same time 47 230 13 24 . . NA
Now and then snus use (n =415,
2.9%)
Began using snus before cigarettes 11 10 2 6 . . NA
Began using snus after cigarettes 100 137 13 20 . . NA
Only used snus, no cigarettes NA NA NA NA NA NA 60
Began using both at same time 20 22 3 11 . . NA
Never used snus (n = 10305, 71.5%) 2120 2950 158 238 139 463 4237
*Ever ‘‘party’’ smokers did not contribute ages at onset of tobacco use, so we could not calculate the age they started smoking in relation to snus use.
NA, not available.
Table 2 Age adjusted odds ratios (OR) (95% confidence intervals (CI)) for ‘‘regular’’ and
‘‘now and then’’ snus use in relation to any lifetime cigarette smoking among males in the
Swedish Twin Registry
Ever smoker* Never smoker OR (95%CI)
Regular snus use 262 4.1% 976 18.5% 0.2 (0.2 to 0.3)
Now and then snus use 29 0.5% 60 1.1% 0.5 (0.3 to 0.7)
Never used snus 5466 95.4% 4237 80.4% 1.0
*’’Ever smoker’’ includes men who reported smoking ‘‘regularly’’ and ‘‘now and then’’. Men who smoked ‘‘at
parties’’ were excluded since they did not contribute ages at onset of tobacco use.
Men who began using snus before cigarettes.
Table 3 Age adjusted OR (95% CI) for smoking cessation (former versus current smokers)
by snus use among males in the Swedish Twin Registry
Former smoker Current smoker OR (95% CI)
Regular snus use 1771 34.6% 381 13.7% 3.7 (3.3 to 4.2)
Now and then snus use 157 3.1% 113 4.1% 1.1 (0.9 to 1.4)
Never used snus 3188 62.3% 2278 82.1% 1.0
*’’Former smokers’’ and ‘‘current smokers’’ includes men who reported smoking ‘‘regularly’’ and ‘‘now and then’’.
Men who smoked ‘‘at parties’’ were excluded since they did not contribute ages at onset of tobacco use.
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What this paper adds
This brief report presents findings that Swedish snus (oral
snuff) is being used as a naturalistic form of nicotine
replacement therapy. We suggest that randomised clinical
trials be conducted to assess the efficacy of snus as a smoking
cessation aide and to evaluate whether any adverse health
consequences result.
424 Furberg, Bulik, Lerman, et al
www.tobaccocontrol.com
